Theriva Biologics Inc. (TOVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE MKT
Market Cap: $6.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Theriva Biologics Inc. (TOVX) Stock Forecast
Analysts expect Theriva Biologics (TOVX) to earn -$0.25 per share in the fiscal year ending Dec 31, 2026, on revenue of $300000. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.20.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.25
- EPS consensus, revenue $300000
- Fiscal year ending Dec 31, 2027
- -$0.20
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.25 to -$0.25 | 1 | $300000 | $300000 to $300000 | 1 |
| Dec 31, 2027 | -$0.20 | -$0.20 to -$0.20 | 1 | N/A | N/A | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.06 for the quarter ending Dec 31, 2026 to -$0.05 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.06 to -$0.06 | 3 |
| Mar 31, 2027 | -$0.05 | -$0.05 to -$0.05 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.20.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.25 | -$0.20 | -$0.20 | -$0.20 | -$0.20 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.20 | -$0.20 | -$0.20 | -$0.20 | -$0.20 | N/A |
Frequently Asked Questions About TOVX
What is the TOVX stock forecast?
Consensus analyst estimates put Theriva Biologics's EPS at -$0.25 for the fiscal year ending Dec 31, 2026, on revenue of $300000.
What EPS do analysts expect from TOVX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.25, with estimates from -$0.25 to -$0.25 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.20, with estimates from -$0.20 to -$0.20 from 1 analyst.
What revenue do analysts expect from Theriva Biologics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $300000, with estimates from $300000 to $300000.
How many analysts cover TOVX?
1 analyst estimates EPS for Theriva Biologics for the fiscal year ending Dec 31, 2026.
TOVX pages: Overview, Earnings, Forecast, Financials, Competitors